Oral Administration of the Pimelic Diphenylamide HDAC Inhibitor HDACi 4b Is Unsuitable for Chronic Inhibition of HDAC Activity in the CNS In Vivo

Oral Administration of the Pimelic Diphenylamide HDAC Inhibitor HDACi 4b Is Unsuitable for Chronic Inhibition of HDAC Activity in the CNS In Vivo. Beconi M, Aziz O, Matthews K, Moumné L, O’Connell C, et al., PLoS ONE 7(9): e44498. doi:10.1371/journal.pone.0044498 (2012)
 OPEN ACCES, FULL TEXT PDF

 Keywords: Histone deacetylase (HDAC) inhibitors, neurological disorders, pimelic diphenylamide HDAC inhibitors, Friedreich’s ataxia, Huntington’s disease.